IMTX250117C14000
- 0.26
- 0.000.00%
Immatics Newsroom
Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Mizuho Securities Sticks to Its Buy Rating for Immatics (IMTX)
Goldman Sachs Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $13.5
Immatics Analyst Ratings
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $15
Jefferies Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $20
Leerink Partners Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $18
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $15
Immatics' Promising Immunotherapy Developments Bolster Jonathan Chang's Buy Rating
Piper Sandler Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $19
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics
Immatics Initiated at Overweight by Piper Sandler
Immatics Analyst Ratings
Piper Sandler Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $19
Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Remains a Buy on Immatics (IMTX)
Immatics Analyst Ratings
Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Buy Rating for Immatics: Promising Clinical Trials and Strong Financials Signal Upside Potential